Privium Fund Management B.V. Invests $1.54 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Privium Fund Management B.V. has acquired a new stake in Alnylam Pharmaceuticals, purchasing 5,716 shares valued at approximately $1.54 million, making it the firm's 27th largest position.
• Analysts have a positive outlook on Alnylam Pharmaceuticals, with 23 out of 27 analysts issuing buy ratings and a revised price target range between $348.00 and $550.00.
• Alnylam's CEO recently sold 19,297 shares valued at nearly $5.9 million, reducing her ownership in the company by 28.3% following the transaction.

Privium Fund Management B.V. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 5,716 shares of the biopharmaceutical company's stock, valued at approximately $1,543,000. Alnylam Pharmaceuticals comprises approximately 0.4% of Privium Fund Management B.V.'s investment portfolio, making the stock its 27th largest holding.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. PNC Financial Services Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 4.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 13,125 shares of the biopharmaceutical company's stock valued at $3,544,000 after acquiring an additional 585 shares during the last quarter. Commerce Bank lifted its stake in shares of Alnylam Pharmaceuticals by 1.2% in the 1st quarter. Commerce Bank now owns 4,557 shares of the biopharmaceutical company's stock valued at $1,230,000 after acquiring an additional 55 shares during the last quarter. Tredje AP fonden lifted its stake in shares of Alnylam Pharmaceuticals by 63.3% in the 1st quarter. Tredje AP fonden now owns 15,907 shares of the biopharmaceutical company's stock valued at $4,295,000 after acquiring an additional 6,165 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $402,000. Finally, S&CO Inc. raised its position in Alnylam Pharmaceuticals by 74.8% during the 1st quarter. S&CO Inc. now owns 10,050 shares of the biopharmaceutical company's stock valued at $2,713,000 after purchasing an additional 4,300 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Up 2.4%

Shares of Alnylam Pharmaceuticals stock traded up $9.56 during midday trading on Friday, hitting $401.80. The company had a trading volume of 1,780,984 shares, compared to its average volume of 1,117,867. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. The stock has a market capitalization of $52.67 billion, a P/E ratio of -162.67 and a beta of 0.25. The company has a 50 day moving average of $318.24 and a 200 day moving average of $279.01. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $402.43.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 444.38% and a negative net margin of 12.96%. The business's quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.16) EPS. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALNY has been the subject of a number of recent analyst reports. BMO Capital Markets upped their price target on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research report on Tuesday, June 24th. Citigroup upped their price target on Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research report on Friday. Barclays upped their price target on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research report on Friday. Finally, Needham & Company LLC upped their price target on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a research report on Thursday. One analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $392.13.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer owned 48,948 shares in the company, valued at $14,978,088. This represents a 28.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.